Mapping Opportunities for Patent Positions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mapping Opportunities for Patent Positions
Follow-on biologics could unleash the potential of several industries and may even spark economic recovery.


Pharmaceutical Technology
Volume 33, Issue 6, pp. 81-82


Frances Weber
The golden age of biotechnology is about to go platinum. Congress is inching closer to establishing a legal framework under which the US Food and Drug Administration can approve the marketing and sale of generic biologic compounds (follow-on biologics) much in the same way that it approves the marketing and sale of generic small-molecule drugs under the Hatch–Waxman Act.

Whatever the outcome of the current data-exclusivity debate in Washington, the exact terms of the compromise will be important to only a small segment of the pharmaceutical and biotechnology industries. Of greater significance are the opportunities that lie in the development of technology that enables one to demonstrate compliance with standards for establishing similarity and equivalency between follow-on and innovator biological compounds.


Scott D. Locke
The intense debate over a pathway for the approval of follow-on biologics demonstrates the importance of biotechnology to this country and the industry's potential to revolutionize medicine and agriculture. Without question, the enactment of a follow-on biologics approval pathway will unleash their potential, just as the Hatch–Waxman Act did for generic small molecules in the 1980s.

Patents and FDA

Exclusive rights to biological inventions may be obtained under national patent systems, which enable patent holders to prevent competitors from making, using, or selling technologies that embody a claimed invention. As with small-molecule technologies, new compounds, new formulations, and new methods for the manufacture, administration, and use of biologics provide fertile grounds for obtaining patent rights for useful, new, and nonobvious inventions. In the United States, however, pharmaceuticals and biologics require FDA approval before being introduced to the market.Because no current mechanism allows follow-on biologics to receive expedited FDA review, companies that desire to produce these compounds have faced significant delays following traditional new-drug-application procedures. These companies, unlike their generic small-molecule counterparts, cannot simply piggyback on the work of the pioneering biologics companies even after a patent has expired. For patent-protected industries not regulated by FDA, this impediment does not exist.

Incentives lie ahead

If new legislation enables FDA to allow follow-on biologics to come to market faster, then competition for pioneering biologic companies will undoubtedly increase. Because time is money, economic incentives are likely to increase the number of companies that manufacture bioequivalent compounds as well as the number of follow-on biologics brought to market. Innovator companies may see a short-term decrease in profits as a result, but the change should force them to concentrate more on developing new biologics and improving their existing drugs. The combination of increased pressure on pioneer companies and increased opportunities for follow-on biologics companies may cause the biotechnology industry to be one of the first industries to emerge from the current economic downturn.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here